TCGA-BH-A0DT-01A-21R-A12D-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 80
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- UV_RESPONSE_DN+0.430
- TGF_BETA_SIGNALING+0.420
- ESTROGEN_RESPONSE_EARLY+0.390
- APICAL_SURFACE+0.380
- TNFA_SIGNALING_VIA_NFKB+0.370
- APOPTOSIS+0.280
- APICAL_JUNCTION+0.250
- KRAS_SIGNALING_UP+0.240
Top 10 suppressed
- E2F_TARGETS-0.520
- G2M_CHECKPOINT-0.420
- MYC_TARGETS_V2-0.410
- MTORC1_SIGNALING-0.400
- OXIDATIVE_PHOSPHORYLATION-0.350
- DNA_REPAIR-0.280
- MYC_TARGETS_V1-0.280
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- UNFOLDED_PROTEIN_RESPONSE-0.240
- UV_RESPONSE_UP-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AO-A12A-01A-21R-A115-07 | — | A | 0.901 |
| 2 | TCGA-D8-A1JH-01A-11R-A13Q-07 | — | A | 0.893 |
| 3 | TCGA-A2-A0ES-01A-11R-A115-07 | — | A | 0.873 |
| 4 | TCGA-EW-A1J2-01A-21R-A13Q-07 | — | A | 0.871 |
| 5 | TCGA-A2-A0YD-01A-11R-A109-07 | — | A | 0.857 |
| 6 | TCGA-CR-7393-01A-11R-2016-07 | — | — | 0.856 |
| 7 | TCGA-85-6175-01A-11R-1820-07 | — | cohortSQ1 | 0.852 |
| 8 | TCGA-75-7030-01A-11R-1949-07 | — | cohortA1 | 0.851 |
| 9 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.835 |
| 10 | SRR6013585 | — | cohortA1 | 0.834 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.430 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.420 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.390 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.380 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| APOPTOSIS | 0.280 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.230 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.160 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.140 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.130 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.130 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.130 | Remibrutinib | — uncovered |
| HYPOXIA | 0.120 | Idelalisib | — uncovered |